Search 

The New York Structural Biology Center, NYSBC, is an organization of 9 eminent academic research institutions. Founded in 1999, NYSBC is a not-for-profit consortium that provides advanced resources in structural biology to its members and outside users. The Center manages two facilities, its main facility in Manhattan and a crystallography facility at the National Synchrotron Light Source (NSLS and NSLS-­‐II) at Brookhaven National Laboratories (BNL) on Long Island. NYSBC is a global leader in structural biology with unsurpassed instrumentation and expertise whose services include high throughput gene-to-­structure determination, X-­ray crystallography, NMR spectroscopy, Cryo-­electron microscopy and Protein Production.

Founded in 1999 by nine eminent New York academic institutions, the New York Structural Biology Center (NYSBC) is one of the world’s leading centers for structural biology, a field critical for rationally-designed drugs.

Based in Manhattan, we are the only facility in the  US  that  provides  all  three major technologies used in biomolecule structure determination: X-ray crystallography, NMR spectroscopy and cryo-electron microscopy, as well as high quality protein production.

NYSBC works with academic scientists, biopharmaceutical companies and the US government, on a membership or fee-for-service basis, on projects ranging from protein production to structure determination and drug design.

To find out more, please call us (212-939-0660) or visit our website (www.nysbc.org).

More than 175 years ago, Albert Gallatin, the distinguished statesman who served as secretary of the treasury under Presidents Thomas Jefferson and James Madison, declared his intention to establish "in this immense and fast-growing city ... a system of rational and practical education fitting for all and graciously opened to all." Founded in 1831, New York University is now one of the largest private universities in the United States. Of the more than 3,000 colleges and universities in America, New York University is one of only 60 member institutions of the distinguished Association of American Universities

YU School of Medicine is one of the nation’s preeminent academic institutions. For more than 150 years, we have trained thousands of physician-scientists who have helped to shape the course of medical history and enrich the lives of countless people. Through medical education, scientific research, and patient care, we continue to demonstrate our deep, abiding commitment to improving the human condition.

The percentage of NYU graduates who are members of medical school faculties is among the highest in the nation. For most of them, an invaluable part of that training was their service at Bellevue Hospital, one of the nation’s finest municipal hospitals, where NYU physicians have provided clinical and emergency care to
New York City’s poor and immigrant populations for more than a century.

As part of a “biomedical corridor” extending from 23rd to 34th Streets along Manhattan’s East River Drive, our institution is guided by the promise of “translational medicine,” in which scientific discoveries are urgently translated into innovative treatments for patients. To create an environment worthy of rapid medical advances, we are constructing new research and clinical facilities. These state-of-the-art facilities will serve as the home for our physician-scientists who are the intellectual foundation of the School. In addition, we are recruiting a new generation of scholars and teachers who have established national and international reputations. And we are admitting some of the nation’s best and brightest students, many of whom will become tomorrow’s leaders in the medical profession.

Your focus and ours is whether NYU is the right place to pursue your medical education. We hope that this website captures the spirit of the educational enterprise at NYU, as well as the experience of studying medicine in the heart of New York City.

NewYorkBIO brings together over 250 of New York’s bioscience companies, universities, research institutions, and others dedicated to advancing life science research and commercialization.  We are the leading advocate for our industry in New York State.

The New York area is the largest and richest bioscience community in the world: among other assets, the region

• boasts over 60% of Big Pharma national or global HQs;

• supports more than 75,000 direct biotechnology jobs and was named Genetic Engineering News’s #1 region in the US to find a biotech job;

• graduates more life science PhDs than any other region in the US;

• is home to over 25% of the clinical trials in the US; and

• lays claim to the world’s largest concentration of academic medical centers.

We drive innovation and support the development and growth of New York State’s life science industry, our members, and the  community by providing a network for information exchange, shared services, and collective action.

Novapeutics LLC is a preclinical biopharmaceutical company spun-out from the University of Pennsylvania that aims to develop a first-in-class small molecule therapeutic to treat diabetes by regenerating insulin-producing beta cells. Our diabetes drug will be orally active and hopefully to provide a cure for diabetics.

Our mission is to care and cure.

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest their money, their time and their ideas in our company.

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG